Recent Updates
Recently added Catalysts
PDEX

Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2015 SECOND QUARTER AND SIX-MONTH

Key Takeaway: Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 PRO-DEX, INC. ANNOUNCES FISCAL 2015 AND SIX-MONTH RESULTS February 10, 2015 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2015 second quarter ended December 31, 2014. Th

Full Press Release Details

Contact: Richard L. Van Kirk,
Chief Executive Officer
(949) 769-3200
PRO-DEX, INC. ANNOUNCES FISCAL 2015
AND SIX-MONTH RESULTS
February 10, 2015 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2015 second quarter ended December
31, 2014. The Company also filed its Quarterly Report on Form 10-Q for the second quarter of fiscal year 2015 with the Securities
and Exchange Commission today.
Net sales for the three
months ended December 31, 2014 increased $152,000, or 6%, to $2.8 million from $2.6 million for the three months ended December
31, 2013, due primarily to increases in medical device revenues. Gross profit for the three months ended December 31, 2014 increased
$147,000, or 27%, to $696,000 from $549,000 for the same period in 2013. Contributing to this increase were the increase in sales
volume, described above, and the decrease in our accrual for anticipated losses from the development services portion of certain
contracts, which decreased by $103,000 compared to the corresponding period of the prior fiscal year.
(which include selling, general and administrative, and research and development expenses) for the quarter ended December 31, 2014
increased 18% to $1.1 million from $925,000 million in the prior year's corresponding quarter, reflecting primarily our investment
in our newly launched engineering services division.
Loss from continuing
operations for the quarter ended December 31, 2014 decreased by $136,000 to $202,000, compared to a loss from continuing operations
of $338,000 in the corresponding quarter in 2013. Net loss for the quarter ended December 31, 2014 was $192,000, or $0.05 per share,
compared to a net loss of $338,000, or $0.10 per share, for the corresponding quarter in 2013.
Ended December 31, 2014
Net sales for the six
months ended December 31, 2014 increased $193,000, or 4%, to $5.4 million from $5.2 million for the six months ended December 31,
2013, due primarily to increases in medical device revenues, which were partially offset by a decrease in dental product revenues.
Gross profit for the
six months ended December 31, 2014 remained stable at $1.5 million, consistent with the same period in 2013.
(which include selling, general and administrative, and research and development expenses) for the six months ended December 31,
2014 increased 14% to $2.1 million from $1.8 million in the prior year's corresponding period, reflecting primarily the effects
of the Company's investment in our newly launched engineering services division as well as research and
incurred to launch in-house battery manufacturing and increases in legal expenses associated with acquisitions and other non-routine
Loss from continuing
operations for the six months ended December 31, 2014 was $383,000, compared to a loss from continuing operations of $320,000 for
the corresponding period in 2013. Net loss for the six months ended December 31, 2014 was $362,000, or $0.09 per share, compared
to a net loss of $126,000, or $0.04 per share, for the corresponding period in 2013.
The Company has decided
to cease hosting earnings conference calls in the foreseeable future. We are a small public company and our current focus is on
improvement of our financial performance, which includes developing new revenue streams, improving and cultivating our valued customer
relationships, and responding to new opportunities quickly. We will continue to provide timely earnings releases and other press
announcements to keep you apprised of our activities and progress.
About Pro-Dex, Inc.:
operations in California, Michigan and Oregon, specializes in the design, development and manufacture of powered rotary drive surgical
and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets. Its OMS division designs
and manufactures embedded motion control systems serving the medical, factory automation, semi-conductor and scientific research
markets. Its Fineline Molds division manufactures plastic injection molding for a variety of industries. Pro-Dex's products are
found in hospitals, dental offices, medical engineering labs, scientific research facilities and high tech manufacturing operations
Pro-Dex also provides
quality and regulatory consulting services, as well as engineering consulting and placement services through its Engineering Services
Division. For more information, visit the Company's website at www.pro-dex.com.
Statements herein concerning
the Company's plans, growth and strategies may include 'forward-looking statements' within the context of the federal securities
laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations,
beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws.
The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should
refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with
the Securities and Exchange Commission.
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
December 31, 2014 June 30, 2014
ASSETS
Current Assets:
Cash and cash equivalents $ 1,973 $ 3,188
Accounts receivable, net of allowance for doubtful accounts of $26 and $29, respectively 1,115 1,776
Unbilled receivables 1,415 1,073
Other current receivables 22 31
Inventory 2,880 2,600
Prepaid expenses 211 110
Notes receivable 1,205 -
Deferred income taxes 146 115
Total current assets 8,967 8,893
Investments 1,002 1,058
Equipment and leasehold improvements, net 1,562 1,575
Intangibles 334 105
Other assets 80 77
Total assets $ 11,945 $ 11,708
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts payable $ 830 $ 744
Accrued expenses 1,352 1,090
Deferred revenue 501 232
Income taxes payable - 53
Capital lease obligations 11 8
Total current liabilities 2,694 2,127
Deferred income taxes 146 115
Deferred rent 221 243
Capital lease obligations, net of current portion 1 7
Total non-current liabilities 368 365
Total liabilities 3,062 2,492
Shareholders' equity:
Common shares; no par value; 50,000,000 shares authorized; 4,169,481 and 4,211,019 shares issued and outstanding at December 31, 2014 and June 30, 2014, respectively 18,497 18,582
Accumulated other comprehensive income 316 202
Accumulated deficit (9,930 ) (9,568 )
Total shareholders' equity 8,883 9,216
Total liabilities and shareholders' equity $ 11,945 $ 11,708
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF
AND COMPREHENSIVE INCOME (LOSS)
(In thousands, except per share amounts)
Three Months Ended December 31, Six Months Ended December 31,
2014 2013 2014 2013
Net sales $ 2,792 $ 2,640 $ 5,387 $ 5,194
Cost of sales 2,096 2,091 3,863 3,700
Gross profit 696 549 1,524 1,494
Operating expenses:
Selling expenses 186 139 328 231
General and administrative expenses 459 422 950 878
Research and development costs 444 364 829 740
Total operating expenses 1,089 925 2,107 1,849
Operating loss (393 ) (376 ) (583 ) (355 )
Interest expense (2 ) (2 ) (3 ) (4 )
Interest income 4 10 5 10
Gain (loss) from disposal of equipment 1 (6 ) 1 (6 )
Realized gain on sale of investments 59 - 59 -
Loss from continuing operations before income taxes (331 ) (374 ) (521 ) (355 )
Income tax benefit 129 36 138 35
Loss from continuing operations (202 ) (338 ) (383 ) (320 )
Income from discontinued operations, net of income taxes 10 - 21 194
Net loss $ (192 ) $ (338 ) $ (362 ) $ (126 )
Other comprehensive income, net of tax:
Unrealized gain from marketable equity investments 162 148 173 204
Less: Reclassification of realized gains included in net loss (59 ) - (59 ) -
Comprehensive income (loss) $ (89 ) $ (190 ) $ (248 ) $ 78
Basic and diluted net loss per share:
Loss from continuing operations $ (0.05 ) $ (0.10 ) $ (0.09 ) $ (0.10 )
Income from discontinued operations - - - 0.06
Net loss $ (0.05 ) $ (0.10 ) $ (0.09 ) $ (0.04 )
Weighted average common shares outstanding:
Basic 4,170 3,343 4,190 3,344
Diluted 4,170 3,343 4,190 3,344
Common shares outstanding 4,170 3,343 4,170 3,344
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF
Six Months Ended December 31,
2014 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (362 ) $ (126 )
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization 259 283
Gain on sale of investments (59 ) -
Gain on sale of real estate held for sale - (167 )
Loss (gain) on retirement of equipment (1 ) 6
Share-based compensation 11 31
Deferred income tax benefit (77 ) -
Allowance for doubtful accounts receivable (3 ) 7
Changes in operating assets and liabilities:
Accounts receivable and other current receivables 673 (259 )
Unbilled receivables (342 ) (367 )
Inventory (275 ) 282
Prepaid expenses and other assets (103 ) (8 )
Accounts payable, accrued expenses and deferred rent 326 (422 )
Deferred revenue 269 106
Income taxes payable (53 ) (6 )
Net cash provided by (used in) operating activities 263 (640 )
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of investments (12 ) (329 )
Purchases of equipment and leasehold improvements (209 ) (19 )
Acquisition of Huber Precision (209 ) -
Purchase of notes receivable (1,205 ) -
Proceeds from sale of real estate held for sale - 900
Proceeds from sale of equipment 1 4
Proceeds from sale of investments 318 -
Increase in intangibles (61 ) (40 )
Net cash provided by (used in) investing activities (1,377 ) 516
CASH FLOWS FROM FINANCING ACTIVITIES:
Purchase of common stock (94 ) -
Payments made for common stock rights offering (3 ) -
Principal payments on capital lease (4 ) (2 )
Net cash used in financing activities (101 ) (2 )
Net decrease in cash and cash equivalents (1,215 ) (126 )
Cash and cash equivalents, beginning of period 3,188 1,680
Cash and cash equivalents, end of period $ 1,973 $ 1,554
Last updated: Feb 10, 2015